Exegenesis Bio
Exegenesis Bio is a clinical-stage global cell and gene therapy company founded in 2019 with operations in Philadelphia, Boston, China, and Singapore. The company focuses on developing innovative genetic medicines for CNS, ophthalmology, and liver-directed diseases, with a vision to increase access to these therapies worldwide. Exegenesis Bio has built a broad pipeline and fully integrated manufacturing capabilities, including AAVarta® for AAV capsid in silico evolution, Constellation® for AI-aided DNA expression cassette design, and Progress® for data-driven protein engineering. The company is advancing early to clinical-stage gene therapies and has received FDA clearance for its IND application for EXG102-031 for neovascular Age-Related Macular Degeneration (nAMD).
Exegenesis Bio
Exegenesis Bio is a clinical-stage global cell and gene therapy company founded in 2019 with operations in Philadelphia, Boston, China, and Singapore. The company focuses on developing innovative genetic medicines for CNS, ophthalmology, and liver-directed diseases, with a vision to increase access to these therapies worldwide. Exegenesis Bio has built a broad pipeline and fully integrated manufacturing capabilities, including AAVarta® for AAV capsid in silico evolution, Constellation® for AI-aided DNA expression cassette design, and Progress® for data-driven protein engineering. The company is advancing early to clinical-stage gene therapies and has received FDA clearance for its IND application for EXG102-031 for neovascular Age-Related Macular Degeneration (nAMD).